High-dose treatment with ADXS11-001, a Listeria monocytogenes-listeriolysin O (Lm-LLO) immunotherapy, in women with cervical cancer: a phase I, dose-escalation study A prospective phase 2 trial (GOG-0265) of the Listeria based HPV immunotherapy axalimogene filolisbac Uploaded: March 23, 2017A Phase 1/2 study of durvalumab alone or in combination with AXAL in recurrent/persistent or metastatic cervical or human papillomavirus (HPV)+ squamous cell cancer of the head and neck (SCCHN): Preliminary Phase 1 results AIM2CERV: a randomized phase 3 study of adjuvant AXAL immunotherapy following chemoradiation in patients who have high-risk locally advanced cervical cancer (HRLACC) Combination of Listeria-based human papillomavirus (HPV)-E7 cancer vaccine (AXAL) with CD137 agonistic antibody provides an effective immunotherapy for HPV+ tumors in a mouse model ADXS11-001 immunotherapy in squamous or non-squamous persistent/recurrent metastatic cervical cancer: Results from stage 1 [and stage 2] of the phase II GOG/NRG-0265 study Poster Uploaded: June 6, 2016ADXS11-001 immunotherapy in squamous or non-squamous persistent/recurrent metastatic cervical cancer: Results from stage 1 [and stage 2] of the phase II GOG/NRG-0265 study Presentation AACR research reception presentation; featuring late-breaking poster on Lm Technology™ platform HPV E7 antigen-expressing Listeria-based immunotherapy (ADXS11-001) prior to robotic surgery for HPV-positive oropharyngeal cancer enhances HPV-specific T cell immunity – AACR 2016 Phase 1/2 study of ADXS31-142 and pembrolizumab in metastatic castration-resistant prostate cancer (mCRPC): The KEYNOTE-046 trial – SITC 2015 Phase 1/2 study of ADXS11-001 or Durvalumab in recurrent/metastatic cervical or HPV-positive head and neck cancer – SITC 2015 High-dose treatment with ADXS11-001 in women with cervical cancer – SITC 2015 Stage 1 Clinical Data from Phase 2 GOG 0265 Study in Metastatic Cervical Cancer - AGOS 2015 Immunotherapy of Breast Cancer - World Congress on Breast Cancer Combination Lm-LLO Immunotherapy plus Radiation Delays Tumor Progression and Prolongs Survival in Osteosarcoma Phase 1 study evaluating high-dose ADXS11-001 treatment in women with carcinoma of the cervix Window of opportunity trial of HPV E7 antigen-expressing Listeria-based therapeutic vaccination prior to robotic surgery for HPV-positive oropharyngeal cancer Phase I study evaluating high dose ADXS11-001 treatment in women with carcinoma of the cervix Window of opportunity trial of HPV E7 antigen-expressing Listeria-based therapeutic vaccination prior to robotic surgery for HPV-positive oropharyngeal cancer Agonistic antibodies to co-stimulatory molecules, OX40 and GITR, significantly enhance the anti-tumor efficacy of Listeria monocytogenes (Lm-LLO)-based immunotherapy Anti-Tumor Therapeutic Effects in Mice Treated with Listeria Monocytogenes (Lm)-LLO Immunotherapy in Combination with Anti-PD-L1 LM-LLO-HER2/NEU Immunotherapy Combined with Radiation Safely Delays Tumor Progression and Prolongs Overall Survival in a Phase I Clinical Study in Canine Osteosarcoma A Phase 1/2 Evaluation of ADXS11- 001 Lm-LLO Immunotherapy, Mitomycin, 5-Fluoruracil (5-FU) and IMRT for Anal Cancer ADXS11-001 Lm-LLO Cancer Immunotherapy: Final Results and Long-Term Survival Data From a Randomized Phase 2 Study in Recurrent Cervical Cancer A recombinant HER2/Neu expressing Listeria monocytogenes (Lm-LLO) immunotherapy delays metastaAc disease and prolongs overall survival in a spontaneous canine model of osteosarcoma Lm-LLO Immunotherapies Targeting Multiple Antigens and Their Impact on Different Mechanisms in the Tumor Microenvironment ASCO Annual Meeting 2014 Poster American Society of ClinicalOncology Annual Meeting 2013 Poster Society for Immunotherapy of Cancer Annual Meeting 2013 Poster Society for Immunotherapy of Cancer Annual Meeting 2013 Poster Uploaded: Nov 8, 2013 
